MRM Health Archives | Be Korea-savvy

Home / Posts tagged MRM Health

MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis

GHENT, Belgium, June 28 (Korea Bizwire) – MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with [...]

MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis

GHENT, Belgium, June 7 (Korea Bizwire) – MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of preclinical research relating to its ongoing program in non-alcoholic fatty liver disease (NAFLD), with a 9-strain live bacterial consortium resulting from its proprietary and unique CORAL® platform technology. The research was conducted in collaboration [...]

MRM Health to Present at the 6th Microbiome Movement Drug Development Europe Summit

GHENT, Belgium, Jan. 26 (Korea Bizwire) – MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that it will present scientific data from its portfolio at the 6th Microbiome Movement Drug Development Europe Summit, resulting from its proprietary and unique CORAL™ platform technology. CEO Sam Possemiers will present MRM Health’s Microbiome Consortia [...]

MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis

GHENT, Belgium, Dec. 8 (Korea Bizwire) – MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that the first patient received MH002 in a phase 1b/2a multi-center clinical trial in mild-to-moderate Ulcerative Colitis. MH002 is MRM Health’s first clinical product candidate resulting from its proprietary and unique CORAL™ platform technology. “We are [...]

MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis

GHENT, Belgium, Sept. 28 (Korea Bizwire) – MRM Health, a biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 1b/2a trial with the novel next-generation optimized consortium therapy, MH002, in patients with mild-to-moderate [...]